Summary.-Tumour experiments including local control after X-irradiation have been performed, using a new technique that eliminates the need for anaesthetics in restraining the animals. This system has been used to investigate the degree of sensitization that can be achieved with ICRF 159 and 4 strongly electron-affinic radiosensitizers, nifurpipone dihydrochloride, metronidazole, Ro-11-3696 and Ro-07-0582.
OXYGEN is metabolized as it diffuses through the cells surrounding a capillary blood bessel, thus producing an 02 gradient such that little or none remains at about 150 /am from the capillary (Thomlinson and Gray, 1955) . The resultant hypoxic cells, which have been demonstrated in animal tumours (e.g. Thomlinson, 1960; Hewitt, Chan and Blake, 1967) , are thought be a reason why X-ray treatment may sometimes fail in the local control of tumours (Fowler, 1972) .
One method of overcoming the problem of hypoxic cell radioresistance is by the use of chemicals which may act, either by normalizing " the developing tumour blood vasculature (Hellmann and Murkin, 1974) , or are electron-affinic compounds which mimic the radiosensitizing effect of 02, but which are not rapidlv metabolized and so can diffuse further and radiosensitize the hypoxic' cells (Adams, 1973) . The present work is concerned with the use of such chemicals to overcome hypoxic cell radioresistance, using the local control (i.e. cure) of tumours in mice irradiated without anaesthetic as the test system.
Five compounds have been investigated: ICRF 159 which has previously been reported to " normalise " blood capillaries within tumours and so promote an improved 02 supply (Hellmann and Murkin, 1974) , and 4 electron-affinic hypoxic cell radiosensitizers nifurpipone dihydrochloride, metronidazole, , which have all shown radiosensitization in vitro (Asquith et al., 1974a (Asquith et al., , 1974b Chapman, Reuvers and Borsa, 1973;  Adams, Asquith and 'Watts, 1974; Adams et al., 1976) . the anaplastic MT tumour, arose spontaneously in a WHT/Ht mouse in 1964 in Dr Hewitt's colony at the Gray Laboratory, and has been maintained since in the same inbred strain of mice. Its volume-doubling time was about 1 day at the size used.
The tumour was aseptically cut into fragments of less than 1 mm, and by means of a fine trocar was implanted s.c. over the sacral region of the back. The mice were anaesthetized with 60 mg/kg pentobarbitone sodium during implantation. Tumours reaching a mean diameter of 5-5 i 0 5 mm between 7 and 21 days after implant were selected for treatment, whilst slower or faster growing tumours were rejected.
Irradiations.-The mice were irradiated without anaesthetic. This was achieved by designing individual mouse boxes consisting of a lead tube with a perspex window and air vent at the head end and a lockable perspex door at the tail end (Fig. 1) (Fig. 1) . The X-ray doses at the 3 paired positions were within 0-5% of each other as checked by a Baldwin-Farmer dosimeter. To ensure uniform doses throughout the tumour volume, the mice were turned through 180°halfway through each irradiation.
Hypoxta.-This was produced using Dshaped metal clamps similar to those described by Denekamp and Harris (1975) .
Ten minutes before starting the irradiations the clamps were applied across the base of the tumour, thus occluding the blood supply.
TCD50 determinations.-The single dose of X-rays required to achieve local control of 50% of the tumours (i.e. TCD50) was determined by treating groups of about 12-18 mice with a range of X-ray doses. The resulting response curve, TCD50 value, and standard error of the mean were computed using the logit method of calculating the maximum likelihood. The programme was revised from that described by Suit, Shalek and Wette (1965) , with the help of Mrs Irene Lansley.
Drugs.-The effect of 5 radiosensitizing drugs on the TCD50, and on the incidence of pulmonary metastases observed post mortem was investigated. The LD50 of each drug was also determined in mice ofthe same strain, age, and sex.
(1) ICRF 159: (Razoxane); [1, 2-di (3,5-dioxopiperazin-1 -yl) Importance of radiation dose on the effectiveness of Ro-07-0582.-This was investigated by comparing the tumour-control results (which used curative doses) with those from a tumour-regrowth delay experiment (which used non-curative doses), when in both cases the mice had been injected i.p. with 1 mg/g Ro-07-0582 30 min before the irradiation started. In the regrowth experiment, calipers were used to measure 3 mutually perpendicular diameters of the tumours daily; and delay in reaching a geometric mean diameter of 10 mm was determined.
RESULTS
Criteria for determining local tumour control Fig. 2 shows the growth of the tumours after single dose of X-rays. The tumours continued to increase in size for about 3 days after irradiation, and then gradually shrank. With doses of 60 gray (6000 rad) or more, the tumours regressed to preirradiation size after about 10 days. For the tumour to become nonpalpable required more than 70 gray and this did not occur until about 21 days. However, the acute skin reaction which was present at this time made palpation difficult, and the earliest accurate assessment to determine the presence or absence of tumour was not feasible until 40 days.
Assessments from the first 20 experiments in which mice were kept up to 300 days revealed that, of those tumours 77-6, 80.0, 77-1, 75-8 and 80-4 gray. The result derived from combining all these data in a single determination of the TCD50, which has been
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used as the control in the present work, was 79-0 gray. These combined data, together with that from the other experiments, are shown in Table I . The TCD50 obtained after irradiating under fully hypoxic conditions (using the tumour clamps) was 77-8 gray, 1-2 gray less than the combined control TCD50 given above. This difference is not significant (it is within 1 s.e.), but indicates that 78-100% of the cells were hypoxic.
Figs 3-6 show the effect of the 5 sensitizing drugs on the control probabilities for tumours in air-breathing mice.
In each figure the combined control line is shown on the right hand side. The curves for different drug-treated groups are all displaced to the left, i.e. showing greater sensitivity. The degree of radiosensitization (i.e. reduction in X-ray dose required to control 50% of the tumours) observed for each of the drugs has been summarized in Table II as the Enhancement Ratio (ER).
Tumour regrowth delay
In an experiment using non-curative single doses of X-rays, the mean delay in Metastases Table I shows the incidence of pulmonary metastases observed post mortem in all the experimental groups. The incidences are expressed as a percentage of the number of mice irradiated in each group.
The incidence in the control group which received X-rays only was 5% (14/281). The significance of any difference between the incidence of metastases in the drug-treated mice and this control value was assessed by the chisquared test. Because of the small numbers of animals available for analysis, the differences are not statistically significant.
DISCUSSION
The present work has shown that in mice kept up to 300 days after treatment, the vast majority of tumours that are going to recur have done so by 60 days, because of the tumours' fast growth rate.
Consequently, if analysed at 80 days rather than 60 days, the TCD50 only increased on average by 0-6 gray (i.e. < 1 %). Nevertheless, 80 days was taken as the end point for analysis.
Assuming that factors such as cell loss and growth fraction remain constant, and that the volume-doubling rate is not slower in an irradiated tumour than an unirradiated tumour, since the tumour has a volume-doubling time from 5*5 mm (size at irradiation) to 6-9 mm mean diameter of 1 day (Fig. 2) , 80 volume doublings were theoretically possible in the 80 days. This is a longer relative delay than we have used in assessing another tumour-control system: the C3H mouse mammary carcinoma (Fowler et al., 1975) . With that tumour, which has a volumedoubling time from 6-5 mm (size at irradiation) to 8-2 mm mean diameter of about 6 days, only 25 volume doublings were theoretically possible in the 150 days used.
The MT tumour is very radioresistant (TCD50 of 79 gray) and appears to be virtually all hypoxic, as judged from the lack of change when the tumour is clamped. This is in conflict with the hypoxic fraction of 5 % found by McNally who irradiated the tumour cells in situt, but excised the tumours immediately afterwards and assayed the surviving fraction 800 RADIOSENSITIZERS AND X-RAY CONTROL OF TUMOURS in vitro. However, this may be explained by the different abilities of oxic and chronically hypoxic cells of the tumour to recover from potentially lethal damage (PLD) (McNally and Sheldon, 1977) .
The presence of hypoxic cells in the MT tumour was a requisite in order to observe sensitization by specific hypoxic cell radiosensitizing drugs. Four such electron-affinic radiosensitizers were investigated, and found to be most effective in the order Ro-07-0582, metronidazole, Ro-11-3696 and nifurpipone dihydrochloride. The other sensitizer tested, ICRF 159, was not thought to act in the same way, and was found to be the least effective.
The electron-affinic drugs used were all nitro-heterocyclic, 3 of them being nitroimidazoles, and the fourth a nitrofuran. They have all been shown to be effective radiosensitizers in vitro, and two of them, Ro-07-0582 and metronidazole, have already been shown to be so effective in a variety of animal tumours that they are already being tested in phase I and II clinical trials.
The in vivo toxicity of a potential radiosensitizer is a major factor in determining its relative usefulness. Unfortunately, the precise nature of the toxicity of the compounds used in the present work is poorly documented. However, the nitroimidazole and nitrofuran compounds are primarily neurotoxic (Olivarius, 1956; Scharer, 1972) , whereas ICRF 159 produces bone marrow depression and intestinal toxicity (Bakowski, 1976) .
The compounds will be discussed in order of their apparent effectiveness in the MT tumour.
Relative effectiveness of the compounds as radiosensitisers
The relative effectiveness of the different compounds as radiosensitizers depends upon the degree of sensitization that can be obtained for an equal level of toxicity. We have achieved this by plotting the enhancement ratio (ER) against the concentration of drug expressed as a percentage of the LD50 required to achieve that enhancement (Fig. 8) It can be seen that the most promising compounds are the nitroimidazoles. For a given level of toxicity, the 2-nitroimidazole, Ro-07-0582, was more effective than either of the 5-nitroimidazoles, metronidazole or Ro-11-3696. As Ro-11-3696 has the same 2-hydroxy-3-methoxypropyl side chain as Ro-07-0582, the point of substitution of the nitro group, rather than the nature of the side chain, would appear to be the major factor determining the relative effectiveness of a nitro-imidazole as a radiosensitizer in vivo.
The nitrofuran, nifurpipone dihydrochloride, was not as effective as the nitroimidazoles, a high toxicity producing only a modest level of sensitization.
The least effective compound was ICRF 159, although neither we nor other workers have tested this compound systematically over a range of doses.
Ro-07-0582 is a small uncharged molecule which has an octanol: water partition coefficient of 0 4 . It has been shown to radiosensitize both anoxic bacteria and mammalian cells cultured (Asquith et al., 1974b (Foster, unpublished) . These concentrations in culture medium give ERs of 1-9 and 2-4 . The half-life of Ro-07-0582 has been determined in serum and in gross tumour samples, both in mouse and in man. The half-life is onlv 1-1 I h in mouse serum (Foster, unpublished) whereas it is 10-18 h in man . Because of this shorter half-life in the mouse, the interval between injection and irradiation is important. Fig. 6 and Table II show that the observed sensitization was greater with a 30-min interval than with a 90-min interval, for a low drug dose of 0-2 mg/g. This is compatible with the decline in serum concentration from 210 ,ug/ml at 30 min to 130 pig/ml at 90 min for a similar dose (0.25 mg/g) (Foster, unpublished) .
The clinical tolerance to Ro-07-0582 has also been determined in tests of this compoound as a tumour radiosensitizer.
Single doses of 140 mg/kg are tolerated (Grav et al., 1976) , yielding serum concentrations of 220 ,ug/ml, somewhat higher than for an equivalent body dose in mice.
This may-also result in a higher tumour concentratioin, since mouse tumours have been shown generally to contain < 4000 of the serum level, whereas human tumours attain about 90%o of the serum concentration, probably because of the differences in half-lives (Dische et al., 1977) .
Thus, the ER of 1 6 obtained for 0-2 mng/g of this drug is perhaps an underestimate of the sensitization that would be achieved for hypoxic cells in human tumours. However, because all tumour cells are not hypoxic, the effect of the sensitizer will be maximal only with large radiation doses. The regrowth-delay experiments showed that the ER for 1 mg/g Ro-07-0582 was only 1P5 for low radiation doses, although it increased as the radiation dose increased above 25 gray, to give an ER of 1 8 for 30 gray X-rays (in the tumour-control experiment, the ER was 2-1 for 38 grav). Although no " break point " is detectable in Fig. 7 , the increase of sensitization as a function of radiation dose supports the idea that less than 80-100 % of the cells are hypoxic. The absence of a " break-point, ", and the increase of sensitization as a function of radiation dose, has also been observed in another tumour, a fibrosarcoma (Denekamp and Stewart, unpublished) .
The change in ER with radiation dose would have obvious clinical implications, as clinical radiation doses per fraction are usually relatively small, and reoxygenation may occur between fractions. However, have already demonstrated an ER of at least 1P2 for a single dose of 8 gray, given to subcutaneous metastases from a human carcinoma of the cervix.
Metronidazole is a 5-nitroimidazole compound verv similar to Ro-07-0582. It is also a small, uncharged molecule, has an octanol: water partition coefficient of 1 1, is slowly metabolized, and has a long serum half-life (Asquith et al., 1974a) . It has been shown to sensitize anoxic bacteria and mammalian cells in vitro, giving a maximum ER in mammalian cells of 1-9 (Foster and Willson, 1973; Chapman et al., 1973; Asquith et al., 1974a) .
In the present work, an ER of 1P5 was obtained for a dose of 10 mg/g and ain ER of 1.2 for a 10-fold lower dose (Fig. 4 , Table II ). These results agree well with those from other studies (Table IV) . The doses administered here should correspond to 100 and 850 p.g/ml serum concentrations (Deutsch et al., 1975) , which in vitro would yield ERs of 193 and 197 respectivelv, close to those observed in vivo.
The clinical tolerance for metronidazole has been established recently in trials of this drug as a potential tumour radiosensitizer. The maximum tolerated dose is about 180 mg/kg, which produces a serum level of 200,ug/ml (Deutsch et al., 1975) . Thus an ER of 1-2 obtained for the lowest dose tested in the anaplastic MT tumour is probably a slight underestimate of what could be achieved clinically, but nevertheless still corresponds to an increase in the local control rate of from 20 to 80% (see Fig. 4 ). Furthermore, metronidazole has already shown a distinct benefit in the treatment of patients with glioblastoma, using an unconventional fractionation scheme of 9 X 3 gray (Urtasun et al., 1976) . The average lifespan of the patients was increased significantly in the metronidazole-treated group. Ro-11-3696 has a 5-nitroimidazole ring structure (like metronidazole) with a 2-hydroxy-3-methoxypropyl side chain (like Ro-07-0582). In mammalian cells in vitro it has been found to be a better radiosensitizer than metronidazole, but not as good as Ro-07-0582. A maximum ER of 2-4 was obtained for 2150 ,ug/ml of Ro-11-3696 in vitro .
In the present work, an ER of 1-3 was obtained with 0 33 mg/g of drug. A direct comparison of this response with that obtained in vitro is not possible, as no serum measurements have been made in mice.
Nifurpipone dihydrochioride, the only nitrofuran tested, is water-soluble, and has been shown specifically to radiosensitize hypoxic mammalian cells in vitro by a factor of at least 2-3 (cf OER 2.7) (Adams et al., 1974) . In vivo, the drug does not appear to be so promising. The drug is more toxic than the nitroimidazoles tested, having an LD50 in WHT/Ht mice of 0 4 mg/g. The maximum ER that has been observed in vivo is 1-45 for artificially hypoxic mouse skin (Denekamp, Michael and Harris, 1974) at a dose of 0.24 mg/g.
At the slightly lower dose used here (0-2 mg/g) the ER was only 1-2 (Fig. 3 Peters, 1976 2 Hellmann & Murkin, 1974 805 which had been injected daily, (from implantation to day of irradiation,) with 30 mg/kg, were given the final injection 60 min before a single X-ray dose.
In the present work, we administered 30 mg/kg ICRF 159 in the same manner as Peters (1976) , but achieved a disappointing ER of only 1 05. Likewise, with a C3H mammary tumour (unpublished), using 30 mg/kg injected for 5 days before a single X-ray dose, with the final injection 60 min before irradiation, we observed Ino radiosensitization.
In conclusion, the effectiveness of ICRF 159 as a radiosensitizing agent in vivo has differed greatly between tumours, and in the present tumour it is much less effective than the other compounds tested.
Effect of radiosensitizing drugs in the development of metastases
The incidence of metastasis is relatively low for this tumour, comprising only about 500 of the mice treated with X-rays above. None of the drugs significantly increased the incidence of pulmonary metastasis. In 2 experiments, using 1 mg/g of Ro-07-0582 and 0 03 mg/g ICRF 159, no metastases were observed, but the groups of mice were not large enough for this reduction from 500 to 000 to be significant at the 500 level of probability. Nevertheless, the reduction in metastases with ICRF 159 is in agreement with that of other workers who have shown that the drug prevents the seeding of metastases (Hellmann and Burrage, 1969; Salisbury, Burrage and Hellmann, 1970; Peters, 1975) . However, in similar TCD50 experiments with the C3H mammary carcinoma, which has a higher natural incidence of metastases, we observed no reduction in the level of metastases (8/30 vs 5/19) in those mice whose tumours were locally controlled (Sheldon and Hill, unpublished) . Since ICRF 159 must be administered from the day of implantation to achieve its antimetastatic effect, and these experiments included administration of 0 03 mg/g/day for only 5 days prior to irradiation, whereas implantation had been performed [2] [3] [4] [5] [6] 
